Form 4: Fennec CFO Robert Andrade Reports Stock Acquisition

Fennec Pharmaceuticals CFO Robert Andrade acquired 1,703 common shares through the release of restricted stock units.

Summary

• Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals, acquired 1,703 common shares on April 30, 2026.
• The acquisition resulted from the release of restricted stock units previously awarded on May 16, 2024, and March 28, 2025.
• Following this transaction, the reporting person holds a total of 287,566 common shares directly.
• The shares were acquired at a price of $0 per share as part of a standard equity compensation vesting event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative vesting of equity compensation rather than a discretionary market trade.

Positives

• The transaction reflects the vesting of equity compensation, aligning the CFO's interests with long-term shareholder value.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of beneficial ownership changes.

Industry Context

StockSavvy.ai notes that routine equity vesting for executive officers is a standard corporate governance practice and does not typically signal a change in market sentiment or company strategy.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation structures in the biotechnology sector.

Stakeholder Impact

• No material impact on shareholders, employees, or other stakeholders.

Next Steps

• None identified.

Key Dates

Keywords

Fennec Pharmaceuticals, FENC, Insider Trading, Form 4, CFO, Equity Compensation